Once-daily tiotropium respimat® add-on therapy has a safety profile comparable with placebo in children and adolescents

Category Primary study
JournalJournal of Allergy and Clinical Immunology
Year 2017
This article has no abstract
Epistemonikos ID: e0ccfed423e09cdaabd6c5d2ad44e7bd92126d0e
First added on: Feb 08, 2025